Company Description

GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on identifying, in-licensing and developing transformative gene therapies. GeneVentiv has two first-in-class gene therapies for patients with significant unmet needs. GENV-HEM is a gene therapy for all hemophilias, including inhibitor patients, and without the durability issues that have plagued Factor VIII gene therapies.